Tal Zaks MD, PhD, Chief Medical Officer at Moderna Therapeutics Discusses Emerging Data For Personalized Vaccine Approach: Safety Profile Was Clean & No Dose Limiting Toxicities, Reached 1mg Dose, Moving Into A Phase 2 Study.
Emerging Data For Personalized Vaccine Approach: Safety Profile Was Clean & No Dose Limiting Toxicities, Reached 1mg Dose, Moving Into A Phase 2 Study
